Precision oncology approach for CCNE1-altered cancers advances with new data, Monte Rosa Therapeutics reports

Traders Union
All News
Business & Wealth
Companies
Monte Rosa unveils CCNE1 data

Top Stories

Editors' Picks

Stocks

Crypto

Economics

Currencies

Commodities

Business & Wealth

Market Voices

Ashutosh Sureka

22.07.2026

Precision oncology approach for CCNE1-altered cancers advances with new data, Monte Rosa Therapeutics reports — Monte Rosa unveils CCNE1 data

Monte Rosa Therapeutics presented preclinical data on its highly selective CCNE1-targeting molecular glue degrader this week at AACR D3.

The research, led by Nina Ilic-Widlund and Bill Tahaney, indicates that CCNE1 molecular glue degraders (MGDs) could offer a differentiated precision medicine strategy for patients with cancers harboring CCNE1 alterations. The findings highlight ongoing innovation in targeted cancer therapies and the potential for new treatments directed at challenging oncogenic drivers.

View post on X Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Monte Rosa Therapeutics recently presented preclinical data for MRT-6160 showing broad disease inhibition in immune-mediated models, according to a company update. The findings support ongoing efforts to develop targeted therapies in oncology and immunology. Ongoing preclinical research further expands the company's pipeline in precision medicine.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Did you like the article?

Editor's Picks for You

Tokens without buyers: Why NFT marketplaces are shutting down

By Mikhail Vnuchkov
3 hours ago

Tokens without buyers: Why NFT marketplaces are shutting down

Editors' Picks

Is it bad to be rich: Why billionaires are seen as villains

By Alena Volkova
6 hours ago

Is it bad to be rich: Why billionaires are seen as villains

Editors' Picks

What is a national blockchain network and does the world need one?

By Olena Litvinenko
Yesterday

What is a national blockchain network and does the world need one?

Editors' Picks

All Editors' Top Picks

Latest Monte Rosa News

Monte Rosa Therapeutics to present Phase 1 MRT-8102 data in CVD risk subjects

By Elena Nikulina
30.09.2026

Monte Rosa Therapeutics to present Phase 1 MRT-8102 data in CVD risk subjects

Companies

Monte Rosa Therapeutics launches patient dosing in MRT-2359 combination study for mCRPC

By Olga Shendetskaya
24.08.2026

Monte Rosa Therapeutics launches patient dosing in MRT-2359 combination study for mCRPC

Companies

Monte Rosa Therapeutics delivers second quarter financial results and advances pipeline momentum

By Ashutosh Sureka
06.08.2026

Monte Rosa Therapeutics delivers second quarter financial results and advances pipeline momentum

Companies

All Monte Rosa News

Mikhail Vnuchkov
3 hours ago

Tokens without buyers: Why NFT marketplaces are shutting down

Alena Volkova
6 hours ago

Is it bad to be rich: Why billionaires are seen as villains

Olena Litvinenko
Yesterday

What is a national blockchain network and does the world need one?

Eugene Komchuk
Yesterday

CertiK expert: Hackers are winning the arms race for now

Dmytro Kharkov
Yesterday

Ledger’s spy chip scandal: Can hardware wallets still guard crypto’s cold storage?

Oksana Koneva
14 min ago

Scott Bessent: Discusses U.S.-Republic of Korea economic and financial relationship with Deputy Prime Minister Lee

Mikhail Vnuchkov
19 min ago

Liz Thomas: S&P 500 gains 14% year-to-date driven by forward EPS growth

Alena Volkova
23 min ago

E.J. Antoni: Existing-home sales up 1.5% in September, median sale price rises 1.3% year over year

Ksenia Gerey
38 min ago

New all-time highs for Magnificent 7 $MAGS do not signal bearishness, Caleb Franzen argues

Yulia Slavina
44 min ago

Simon Dixon: Bitcoin proof of work means ownership does not equal network control

Top News

Eugene Komchuk
1 hour ago

Paul Tudor Jones predicts a challenging 2027 for stock market

Paul Tudor Jones predicts a challenging 2027 for stock market

Ivan Andriyenko
1 hour ago

Brent falls below $105 despite rising tensions in the Gulf

Brent falls below $105 despite rising tensions in the Gulf

Igor Krasulya
3 hours ago

Cathie Wood warns of risks in memory chip stocks

Cathie Wood warns of risks in memory chip stocks

Olga Shendetskaya
7 hours ago

Gold prices rise as Middle East tensions complicate Fed rate outlook

Gold prices rise as Middle East tensions complicate Fed rate outlook

Olga Shendetskaya
8 hours ago

Asian tech shares fall sharply as doubts grow over AI profits

Asian tech shares fall sharply as doubts grow over AI profits

Top 5 companies for you

United States

Live News

Mykhailo Ihnatenko
Now

Nvidia stock tests key support as China competition intensifies

Ivan Andriyenko
Now

U.S. stock futures mixed as chip stocks extend losses

Anton Kharitonov
Now

EUR/USD remains under pressure as dollar strength and European risks weigh on the euro

Ivan Andriyenko
Now

Plus500 acquires Hedge Capital Markets to expand U.S. trading business

Eugene Komchuk
Now

Robbers steal nearly $800,000 from crypto trader in the UK

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.